TABLE 1.
CT alone and 18F-FDG PET/CT performances for LN staging, with pathology as a gold standard, without preoperative chemotherapy.
| First author | Year | CT criteria | PET/CT criteria | Sensitivity |
Specificity |
Accuracy |
|||
| CT | PET/CT | CT | PET/CT | CT | PET/CT | ||||
| Girard (22) | 2019 | SA > 8 mm | SUVmax > 4, and/or SA > 10 mm, and/or SUVmax > 2 and SA > 8 mm | 7/17 | 8/17 | 38/44 | 42/44 | 45/61 | 50/61 |
| Pichler (91) | 2017 | SA > 8 mm | SA > 10mm, and/or PET subjective analysis | 5/11 | 7/11 | 54/59 | 52/59 | 59/70 | 59/70 |
| Uttam (92) | 2016 | SA > 10 mm | SUVmax > 2.5 | 3/3 | 3/3 | 6/12 | 7/12 | 9/15 | 10/15 |
| Jeong (93) | 2015 | SA > 10 mm or necrosis | SUVmax > 2.5 | 5/17 | 8/17 | 43/44 | 41/44 | 48/61 | 49/61 |
| Aljabery (94) | 2015 | LA ≥ 10 mm | SUVmax > 2.5 | 7/17 | 7/17 | 33/37 | 32/37 | 40/54 | 39/54 |
| Rouanne (95) | 2014 | SA > 10 mm | PET subjective analysis | NA | 13/26 | NA | 74/76 | NA | 87/102 |
| Goodfellow (26) | 2014 | SA > 8 mm | SA > 8 mm and/or PET subjective analysis | 13/28 | 19/28 | 64/65 | 62/65 | 77/93 | 81/93 |
| Hitier-Berthault (96) | 2013 | LA > 10 mm | PET subjective analysis | 2/22 | 8/22 | 27/30 | 26/30 | 29/52 | 34/52 |
| Swinnen (97) | 2010 | NA | PET subjective analysis | 6/13 | 6/13 | 35/38 | 37/38 | 41/51 | 43/51 |
| Kibel (33) | 2009 | NA | PET subjective analysis | NA | 7/10 | NA | 30/32 | NA | 37/42 |
| Pooled [95% CI] | 37.5% (48/128) [29.1–46.5%] | 52.4% (86/164) [44.5–60.3%] | 91.2% (300/329) [87.6–94.0%] | 92.2% (403/437) [89.3–94.6%] | 76.1% (348/457) [72.0–80.0%] | 81.4% (489/601) [78.0–84.4%] | |||
SA, short axis; LA, long axis; LN, lymph node; SUVmax, maximum standardized uptake value; NA, not available.